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Prostate cancer development has been associated with changes in mitochondrial activity and reactive oxygen species (ROS)
production. Melatonin (MLT) and docosahexaenoic acid (DHA) have properties to modulate both, but their protective role,
mainly at early stages of prostate cancer, remains unclear. In this study, the effects of MLT and DHA, combined or not, on
PNT1A cells with regard to mitochondria bioenergetics, ROS production, and proliferation-related pathways were examined.
Based on dose response and lipid accumulation assays, DHA at 100 μM and MLT at 1 μM for 48 h were chosen. DHA doubled
and MLT reduced (40%) superoxide anion production, but coincubation (DM) did not normalize to control. Hydrogen peroxide
production decreased after MLT incubation only (p < 0 01). These alterations affected the area and perimeter of mitochondria,
since DHA increased whereas MLT decreased, but such hormone has no effect on coincubation. DHA isolated did not change the
oxidative phosphorylation rate (OXPHOS), but decreased (p < 0 001) the mitochondrial bioenergetic reserve capacity (MBRC)
which is closely related to cell responsiveness to stress conditions. MLT, regardless of DHA, ameliorated OXPHOS and recovered
MBRC after coincubation. All incubations decreased AKT phosphorylation; however, only MLT alone inhibited p-mTOR. MLT
increased p-ERK1/2 and, when combined to DHA, increased GSTP1 expression (p < 0 01). DHA did not change the testosterone
levels in the medium, whereas MLT alone or coincubated decreased by about 20%; however, any incubation affected AR
expression. Moreover, incubation with luzindole revealed that MLT effects were MTR1/2-independent. In conclusion, DHA
increased ROS production and impaired mitochondrial function which was probably related to AKT inactivation; MLT improved
OXPHOS and decreased ROS which was related to AKT/mTOR dephosphorylation, and when coincubated, the antiproliferative
action was related to mitochondrial bioenergetic modulation associated to AKT and ERK1/2 regulation. Together, these findings
point to the potential application of DHA and MLT towards the prevention of proliferative prostate diseases.
1. Introduction
Despite its multifactorial etiology, progression and aggres-
siveness of prostate cancer (PCa) have been related to oxida-
tive stress [1, 2] and the increased production of reactive
oxygen species (ROS) is closely associated to alterations in
the mitochondria [3]. Such organelles play a crucial role in
all stages of malign transformation [3] and have been associ-
ated to PCa due to reduction in apoptotic potential [4], path-
ogenic mutations in genes encoding the electron transport
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chain (ETC) respiratory complexes, and loss of mitochon-
drial DNA and integrity [5]. Therefore, modulation of mito-
chondria physiology may be a good therapeutic target, either
in the prevention of tumor development or in the induction
of cancer cell death.
Melatonin (MLT) is a pleiotropic hormone with antioxi-
dant properties that regulate mitochondrial activity [6–10]
and has been investigated as a PCa suppressor [11]. Patients
with PCa exhibit low MLT serum levels when compared to
healthy individuals, with a notable decrease when benign
prostatic hyperplasia (BPH) progresses to adenocarcinoma
[11, 12]. Most cases of PCa (75%) are diagnosed in men over
65 years [11], coincidental to the period when MLT synthesis
is reduced [13] and mitochondrial dysfunction increases due
to ROS production [14, 15]. Regarding this evidence, MLT
supplementation in patients within risk age of PCa (30–40
years old) may be an interesting chemoprevention strategy
[16]. Apart from its own anticancer properties, MLT has also
been investigated in combination with other compounds,
due to its ability to sensitize cells and potentialize the antipro-
liferative effect of these compounds by inhibition of survival
pathways, e.g., AKT [17]. In this context, polyunsaturated
fatty acids omega-3 (PUFA ω-3), mainly docosahexaenoic
acid (DHA), have been reported to increase mitochondrial
ROS in tumor cells through AKT/mTOR inhibition [18],
leading to cell death. Furthermore, DHA catabolism occurs
in the peroxisome and mitochondria [19] and is very suscep-
tible to oxidation caused by reactive species [20] leading to
generation of cyto- and genotoxic hydroperoxides and alde-
hydes [21]. Although evidence suggests that DHA, a fatty
acid present in the human diet and usually adopted as nutri-
tional supplementation, can exert antiproliferative effects, it
has not yet been investigated in early stages of prostate prolif-
erative disorders, such as benign hyperplasia.
The treatment adopted in most cases of androgen-
dependent PCa is androgen ablation, which can lead to selec-
tive advantage to androgen-independent cancer cells that
eventually proliferate and promote the recurrence of a more
aggressive phenotype [22]. Administration of compounds
that affect sexual steroid pathways also have been a strategy
in prevention and treatment of PCa, but the mechanisms
triggered are still not fully elucidated and their safety is
uncertain [23]. In this context, one of the avenues to decrease
the high mortality rate caused by PCa [24] may be the
chemoprevention focused on the suppression of growth or
survival of abnormal cells at early stages. Therefore, our
aim was to test, in vitro, the antiproliferative potential of
MLT and DHA, combined or not, in early stages of prostate
proliferative disorders. For this purpose, the proliferation of
PNT1A cells, an epithelial benign prostate line sensitive to
androgen, and the correlations to ROS production, mito-
chondrial bioenergetics, and proliferative signaling pathways
were evaluated.
2. Material and Methods
2.1. Cell Culture and Treatments. PNT1A cells
(#95012614—Health Protection Agency, England, UK) were
seeded in RPMI 1640 medium (#R6504—Sigma-Aldrich, St.
Louis, Missouri, EUA) enriched with 10% fetal bovine serum
(#S0011—Vitrocell, Campinas, São Paulo, Brazil), 1% of pen-
icillin, streptomycin, and amphotericin B (#15240062—Life
Technologies, Paisley, UK) and incubated in a wet incubator
with 5% of CO2 at 37
°C. For cell maintenance, the medium
was replaced every 2–3 days and subculture was done when
70–85% confluence was reached. For the experiments, the
cells were incubated at the desired density and were allowed
to attach during 24 hours.
DHA (#D2534—Sigma-Aldrich, St. Louis, Missouri,
EUA) concentrations (10μM, 20μM, 50μM, and 100μM)
were freshly prepared in RPMI 1640 culture medium from
a stock solution of 20mM DHA in anhydrous ethanol
(vehicle), and the effects on cell proliferation at 24 h, 48 h,
and 72h were tested. These concentrations were chosen
according to previous experiments with normal epithelial
prostatic cells RWPE-1 [25]. DHA concentration and time
of incubation that first exerted antiproliferative effects, com-
bined to higher lipid accumulation, were chosen to perform
all forward assays.
Because there are several studies reporting major path-
ways triggered by MLT (#M5250—Sigma-Aldrich, St. Louis,
Missouri, EUA) in different concentrations [26, 27], we first
evaluatedphysiologic (pM–nM), supraphysiologic (nM–μM),
and pharmacologic (μM–mM) ranges on cell proliferation.
Then, the effects of 1 pM, 1nM, 1μM, and 1mMofMLTwere
tested alone or in coincubation with DHA. These MLT con-
centrations in themediumwere freshly prepared from a stock
solution at 100mM in anhydrous ethanol (vehicle), and the
first that exerted antiproliferative effects, alone and combined
to DHA, were chosen for forward assays. For coincubation
assays, DHA and MLT at the desired concentration were
added to themediumat the same time. Proliferation assaywith
luzindole (#15998—CaymanChemical,MI,USA), anonselec-
tive antagonist of MTR1 and MTR2 membrane receptors,
100-fold higher than the MLT work concentration, was per-
formed in control (vehicle incubation only), melatonin
(MLT), DHA, and coincubation (DM) to determine the path-
ways of hormone action.
To ensure that the mechanisms observed were not due to
vehicle, all control assays were incubated with anhydrous
ethanol at the same volume of DHA, MLT, or DM added to
the cells. Also, the concentration of vehicle in the medium
never exceeded 0.5% which did not exert alteration on cell
proliferation (data not shown).
2.2. Cell Proliferation Assay. The effects of treatments were
evaluated after incubation of 1× 104 cells/well with commer-
cial colorimetric kit CellTiter 96® AQueous One Solution
Cell Proliferation Assay (#G3580—Promega Corporation,
Madison, WI, USA), according to the manufacturer’s
instructions. Absorbance was determined at 490 nm in an
Epochmicroplate reader (BioTek Instruments Inc.,Winooski,
VT, EUA). Three independent experiments in triplicate
were performed for statistical analysis.
2.3. Lipid Accumulation. Qualitative evaluation of lipid
uptake was assessed by light microscopic analysis after incu-
bation with Oil Red O (#O0625—Sigma-Aldrich, St. Louis,
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Missouri, EUA). Cells were seeded at 1× 104 cells/well
followed by incubation with DHA (10μM, 20μM, 50μM,
and 100μM) or vehicle (control). After incubation, the
medium was removed, and the cells were washed with PBS
and fixed with paraformaldehyde 4% for 10 minutes. Then,
cells were immersed in isopropanol 60% for 5 minutes at
room temperature (RT) followed by incubation for 60
minutes with fresh Oil Red O prepared at 0.03% in isopropa-
nol. After two independent experiments performed in dupli-
cate, the most representative profile of lipid accumulation
was considered for each DHA concentration.
Quantitative evaluation of intracellular lipids was
assessed after incubation (5× 104 cells/well) with 5μM of
BODIPY™ Lipid Probes 493/503 (#D3922—Molecular
Probes®, Invitrogen) prepared in serum-free medium for 5
minutes at RT, according to the manufacturer’s instructions.
Immediately, images were captured with an inverted fluores-
cence microscope (Axio Vert.A1 Carl Zeiss AG, DE) with the
same time of exposure (280ms). Quantification of total fluo-
rescence intensity was assessed with ImageJ software, and at
least four hundred cells per treatment from three consecutive
passages were considered.
2.4. ROS Determination.Hydrogen peroxide (H2O2) produc-
tion was determined after incubation of 106 cells/mL in PBS/
Mg+2, 5mM of succinate, 1U/mL of HRP, and 25μM of
Amplex Red (Molecular Probes®, Thermo Fisher Inc.). Fluo-
rescence intensity was assessed at 563 nm excitation and
587nm emission, using a Cytation 3 Cell Imaging Multi-
Mode Reader (BioTek Instruments Inc., Winooski, VT,
EUA). Cell H2O2 production was correlated to fluorescence
intensity and calculated as described previously [28]. Three
independent experiments in triplicate were considered for
statistical analysis.
Superoxide anion production (O2
●−) was assessed after
incubation with MitoSOX® Red dye (#M36008—Molecular
Probes, Thermo Fisher Inc.), according to the manufacturer’s
instructions. After treatments, the medium was removed,
and the cells (5× 104/well) were washed twice with KH buffer
(NaCl 120mM, NaHCO3 15mM, KCl 5mM, NaH2PO4
1.5mM, and Na2HPO4 0.7mM) and incubated with the dye
at 3μM for 15 minutes at 37°C in an incubator with 5%
CO2. Then, cells were washed twice with KH buffer to
remove the dye that did not enter the mitochondria. A
total of fifteen images from wells containing cells of con-
secutive passages were captured at the same exposure time
(1200ms) with an inverted fluorescence microscope (Axio
Vert.A1 Carl Zeiss AG, DE). Total field fluorescence inten-
sity was measured with ImageJ software and normalized
with the number of cells per field. At least 250 cells were
counted in each treatment.
2.5. Morphometric Analysis of Mitochondria. Cells were
seeded at a density 5× 104 cells/well in a CELLview bottom
glass (Greiner Bio-One) and, after treatments, incubated with
MitoTracker Orange CMTMRos (#M7510Molecular Probes,
Invitrogen) at 50 nM in a serum-free medium at 37°C and 5%
CO2, according to the manufacturer’s instructions. After 15
minutes, media were replaced and live cells were immediately
analyzed with an inverted fluorescence microscope (Axio
Observer Z1 Carl Zeiss AG, DE). Morphometric evaluation
of mitochondria was done with a macro created for ImageJ
software by Dagda and colleagues [29]. This tool was previ-
ously validated [29] and allows measuring mitochondria
stained with the specific fluorescent dye and determining
the area and perimeter of the organelle. Measurements were
performed in at least fifteen images captured with 40x objec-
tive. Fluorescent regions of each image were measured
followed by normalization of number of cells per field. At
least 100 cells were considered for statistical analysis.
2.6. Mitochondrial Membrane Potential Determination. After
incubations, cells were centrifuged at 2000 rpm for 5 minutes
at 4°C, then the pellets were washed and resuspended in PBS.
Respiration buffer (sucrose 125mM, KCl 65mM, HEPES
10mM pH7.2, MgCl2 1mM, KH2PO4 2mM, EGTA
0.5mM, and BSA 0.15%), 106 cells/mL, succinate 5mM, saf-
ranin O 5μM, and digitonin 20μM were added to a cuvette,
as described by Holden and Sze [30] (concentrations of cells,
succinate, safranin O, and digitonin were adapted for
increased effectiveness without damaging the integrity of
the mitochondria). For analysis, ADP 50μM, oligomycin
1μg/mL (OLG), and antimycin A 1μg/mL (AA) were added
to the incubation medium. Values were recorded in a fluores-
cence spectrophotometer (F-2500 Hitachi) with 495 nm and
589 nm excitation and emission, respectively. The most rep-
resentative profile of mitochondrial membrane potential of
three independent experiments performed in duplicate was
plotted and values shown in arbitrary fluorescence units.
2.7. Oxygen Consumption Rate. Oxygen consumption rate
(OCR) was assessed in a Hansatech Oxygraph (Yellow
Springs Corporation) as described by Silva and colleagues
[31]. Basal state (S2) was determined after incubation of
106 cells/mL in respiration buffer (sucrose 125mM, KCl
65mM, HEPES 10mM pH7.2, MgCl2 1mM, KH2PO4
2mM, EGTA 0.5mM, and BSA 0.15%) in the presence of
digitonin at 20μM and succinate 5mM. State 3 (S3) was
determined by OCR and assessed after the addition of
50μMADP and state 4 (S4) with oligomycin 1μg/mL. Respi-
ratory control (RC) was calculated as RC = state 3OCR/sta
te 4OCR and indicates the oxidative phosphorylation rate.
ETC maximum velocity (S3U) was determined by OCR and
assessed after the addition of mitochondrial uncoupler car-
bonyl cyanide m-chlorophenyl hydrazone (CCCP) at 1μM.
Mitochondrial bioenergetic reserve capacity was calculated
as MBRC = S3U − S2 , as described by Vayalil and Landar
[32], considering nonmitochondrial oxygen consumption.
At least three experiments in triplicate were considered for
statistical analysis.
2.8. Testosterone Level in the Medium. After incubations, the
medium was removed from the wells and testosterone levels
were measured with ELISA assay from an AccuBind Testos-
terone System Microwells (#3725300—Monobind Inc., Lake
Forest, CA, USA) commercial kit, according to the manufac-
turer’s instructions. Concentrations of testosterone (ng/mL)
were normalized by protein amount in the cell lysate from
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the correspondent well. Three independent experiments were
performed in triplicate for statistical analysis.
2.9. Western Blotting. After incubations, cells (5× 104/well)
were lysed in RIPA buffer in the presence of 10% protease
inhibitor cocktail, sodium orthovanadate (1 : 100), and PMSF
(1 : 1000). All reagents were obtained from Sigma-Aldrich
(St. Louis, Missouri, EUA). Protein quantification was per-
formed in an Epoch microplate reader coupled to Take3
Micro-Volume (BioTek Instruments Inc., Winooski, VT,
EUA) at 280nm. After electrophoresis in SDS-PAGE, pro-
teins (50 or 100 μg/μL) were transferred to the nitrocellulose
membrane for 1 hour and 40 minutes in a semidry system.
Nonspecific bindings were blocked with BSA 5% in TBST
for 1 h (phosphorylated proteins) or nonfat milk at 5% in
TBST for 30 minutes (for nonphosphorylated proteins), at
RT in a shaker. Primary antibodies anti-phospho-mTOR
(rabbit monoclonal, Santa Cruz Biotechnology, 1 : 400),
anti-phospho-AKT (rabbit polyclonal, Santa Cruz Biotech-
nology, 1 : 400), anti-phospho-ERK1/2 (rabbit polyclonal,
Cell Signaling, 1 : 1000), anti-GSTP1 (rabbit polyclonal, Cell
Signaling, 1 : 1000), and anti-β-actin (mouse monoclonal,
Santa Cruz Biotechnology, 1 : 1000) were incubated over-
night at 4°C. Secondary antibodies were prepared at 10x dilu-
tion of the respective primary antibody and incubated at 4°C
for 1 h. The ECL system was applied for band visualization
and image capture. All incubations were analyzed in tripli-
cate (n = 3) in the same gel, and one protein per gel in addi-
tion to β-actin for loading control was quantified. Relative
densitometry was assessed using ImageJ software.
2.10. Statistical Analyses. Statistical analyses were performed
with GraphPad Prism® software (GraphPad Prism software,
v.5.0). First, distribution of samples was analyzed with
Kolmogorov-Smirnov and Shapiro-Wilk normality tests.
Parametric distributions were submitted to T test or one-
way ANOVA followed by Tukey test (post hoc); nonpara-
metric distributions toMann-Whitney or Kruskal-Wallis test
followed by Dunn test (post hoc). p < 0 05 was considered
statistically different.
3. Results
3.1. Pro- or Antimitogenic Actions of DHA in PNT1A Cells
Are Time- and Concentration-Dependent. All DHA concen-
trations tested within 24 h, except 10μM, increased the pro-
liferation of PNT1A cells. Stimulation of the clonogenic
rate at 48 h was only observed with 20 and 50μM as well as
10 and 20μM at 72h (Figure 1(a)). At 100μM, the highest
concentration tested, cell proliferation (Figure 1(a)) reduced
only after 48 h (control: 0.41± 0.01; DHA 0.34± 0.01 abs)
and 72h (control: 0.36± 0.01; DHA: 0.20± 0.01 abs). DHA
also stimulated lipid accumulation in a dose- and time-
dependent pattern, as represented in Figure 1(b) for 48 h
incubation. Therefore, 100μM of DHA at 48 h was selected
to perform all forward assays.
3.2. MLT Decreased PNT1A Cell Proliferation. MLT at phys-
iological concentrations (1 pM and 1nM) had no effect on
cell proliferation (Figure 1(c)) but decreased at 1μM
(control: 0.87± 0.02; MLT 0.74± 0.02 abs) and 1mM
(control: 0.81± 0.02; MLT: 0.50± 0.005 abs). At 1μM, MLT
exerted the most antiproliferative effect in comparison to all
concentrations analyzed (Figure 1(c)). We chose MLT at
the concentration of 1μM because it was the first to exert
an antiproliferative effect. Also, our aim was to evaluate the
MLT effects, regardless of membrane receptor activation,
which occurs mainly in the pM–nM range.
3.3. MLT Improved Antiproliferative Effect When Combined
to DHA. MLT coincubated with DHA 100μM for 48 h
roughly decreased cell proliferation (Figure 1(c)) at 1μM
(control: 0.87± 0.02; DM: 0.58± 0.02 abs) and 1mM
(control: 0.81± 0.02; DM: 0.29± 0.01 abs). Coincubation
with MLT at 1mM exhibited the most antiproliferative effect,
decreasing by 50% the cell proliferation rate compared to
DM at 1μM (Figure 1(c)).
3.4. DHA Alone or Coincubated with MLT Increased Lipid
Intracellular Amount. Incubation with DHA alone
(100μM) increased by 62% lipid accumulation in PNT1A
cells after 48 h and, when coincubated withMLT 1μM, raised
to 82% (control: 3.97± 0.19, DHA: 6.66± 0.14, and DM: 7.34
± 0.16 FI/cell× 105). MLT alone did not affect intracellular
lipid storage (Figure 2).
3.5. DHA Increased Superoxide Anion Production and MLT
Alleviated ROS Generation. DHA did not alter H2O2 produc-
tion by PNT1A cells when compared to control (Figure 3(a)).
MLT reduced 62% of total H2O2 production, but when coin-
cubated with DHA, H2O2 generation increased compared to
control, as shown in Figure 3(a) (control: 0.098± 0.007, MLT:
0.037± 0.008, and DM: 0.144± 0.009 pmol/min/106 cells).
DHA doubled whereas MLT alone reduced 40% of super-
oxide anion production (Figures 3(b) and 3(c)) by PNT1A
cells when compared to control. Coincubation attenuated
such ROS production compared to DHA alone, but did not
normalize to control (control: 7.91± 0.73, DHA: 16.78±
1.30, MLT: 4.75± 0.39, and DM: 12.26± 0.65 FI/cell× 104).
3.6. MLT Improved Oxidative Phosphorylation and Alleviated
Mitochondrial Damage Caused by DHA. None of the incuba-
tions altered basal OCR in PNT1A cells (S2—Figure 4(a)).
Respiratory control (Figure 4(b)) was increased by MLT
alone or coincubated whereas DHA did not promote any
change on OCR when compared to control (control: 3.13±
0.08, MLT: 4.89± 0.23, and DM: 3.71± 0.13). Mitochondrial
bioenergetic reserve capacity (MBRC) of PNT1A cells
(Figure 4(d)) was unaffected by MLT alone, decreased
2-fold after incubation only with DHA, and raised roughly
by 130% in DM compared to control (control: 2.90± 0.27,
DHA: 1.59± 0.11, and DM: 3.77± 0.07 nmol O2/106 cells/
min). MLT alone decreased both mitochondrial area and
perimeter, and DHA alone increased as well as coincubation
when compared to control (area—control: 122.1± 5.79,
DHA: 147.1± 5.33, MLT: 89.55± 4.05, and DM: 146.3±
8.04 μm2/perimeter—control: 8.02± 0.28, DHA: 10.03±
0.21, MLT: 6.23± 0.23, and DM: 9.47± 0.48 μm), as shown
in Figures 5(a)–5(c).


































































Figure 1: DHA andMLT antiproliferative effect. (a) PNT1A cell proliferation incubated with 10, 20, 50, and 100μMof DHA after 24, 48, and
72 h. Legend of panel (a): C: control (vehicle incubation). Statistical analysis of panel (a): (A) different from C; (B) different from 10 μM;
(C) different from 20μM; (D) different from 50 μM. (b) Lipid droplets (arrow) stained (red) with Oil Red O (bottom row) after incubation
with vehicle (C) or DHA at 10, 20, 50, and 100 μM for 48 h. Images captured with 40x objective. For qualitative analysis, two independent
experiments were performed in duplicate, and the most representative lipid accumulation for each DHA concentration is shown.
(c) PNT1A cell proliferation incubated with 1 pM, 1 nM, 1μM, and 1mM of MLT after 48 h. Legend of panel (c): C: control
(vehicle incubation); MLT: melatonin incubation; DM: coincubation with 100 μM of DHA and melatonin. Statistical analysis of panel
(c): (A) different from C; (B) different from MLT considering same concentration range; (C) different from MLT-1 pM; (D) different from
MLT-1 nM; (E) different from MLT-1 μM; (G) different from DM-1 pM; (H) different from DM-1 nM; (I) different from DM-1μM;
p < 0 05 was determined as statistically different. All proliferation assays were performed in triplicate, and three independent events
considered for statistical analysis. Values show the mean of absorbance and SEM.
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3.7. MLT and DHA Modulated the Survivor and Cell
Proliferation-Related Pathways Regardless of MTR1 or
MTR2 Sensitization. Luzindole did not change cell prolifera-
tion (Figure 6(f)) in control or MLT, but was reduced when
incubated with DHA (control: 0.65± 0.02; DHA: 0.48± 0.02
abs) and DM (control: 0.51± 0.03; DM: 0.35± 0.02 abs)
compared to incubations without the antagonist.
DHA and MLT alone suppressed AKT phosphorylation
(Figure 6(a)) when compared to control, as well as coincuba-
tion, which did not show a synergistic effect (control: 2.17±
0.12, DHA: 1.33± 0.18, MLT: 1.31± 0.03, and DM: 1.51±
0.15). MLT alone also inhibited mTOR activation
(Figure 6(b)) compared to control, whereas DHA alone or
in coincubation did not change (control: 0.150± 0.015;
MLT: 0.082± 0.003). On the other hand, MLT alone
increased ERK1/2 phosphorylation (Figure 6(c)) compared
to control and coincubation with DHA amplified this
effect (control: 0.045± 0.005, MLT: 0.125± 0.009, and DM:
0.223± 0.021). GSTP1 expression (Figure 6(d)) did not
change in isolated incubations, but together, MLT and
DHA increased 20% compared to MLT alone (MLT: 1.69±
0.10; DM: 2.34± 0.17).
3.8. MLTMay Influence the Androgen Pathway. Testosterone
levels in culture medium (Figure 7) decreased by 25% after


































Figure 2: Lipid accumulation. (a) Detection of lipids (green) in PNT1A cells with BODIPY. Cells were incubated with 100 μM of DHA and
1μM of MLT for 48 h before the dye. Images of left column were captured with 10x objective and right column (insets) with 40x. (b) Lipid
storage quantification. C: control (vehicle incubation); DHA: incubation with 100μM of DHA for 48 h; MLT: incubation with 1 μM of
melatonin for 48 h; DM: coincubation with 100μM of DHA and 1 μM of melatonin for 48 h. Statistical analysis: (A) different from C;
(B) different from DHA; (C) different from MLT. p < 0 05 was considered statistically different. At least four hundred cells per treatment
from three consecutive passages were analyzed. Values show the mean of fluorescent units per cell and SEM.
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coincubated with DHA, whereas no alteration was observed
for DHA alone (control: 11.20± 0.15, MLT: 8.60± 0.64,
DM: 9.18± 0.43 ng/mL× 10−5). AR expression did not
change among any incubation (Figure 6(e)).
4. Discussion
Considering that the available strategies against PCa are still
highly inefficient and may lead to the recurrence of more
aggressive phenotypes [22, 23], we investigated, in vitro, the
potential of DHA and MLT to decrease cell survival at early
stages of proliferative disorders. PNT1A cells were chosen
due to their normal secretory phenotype but also nonmalig-
nant alterations, allowing study growth and survival of high
proliferative prostate cells which are sensitive to androgen,
as described in early stages of prostate cancer progression
and BHP [33]. Furthermore, this cell line retains AR expres-
sion, whose activity is closely related to cell metabolism, and
the loss thereof affects mitochondria yields and dynamics
among PCa progression. Due to their antiproliferative prop-
erties, DHA and MLT have been investigated as PCa sup-
pressors in experimental studies [11, 18], but their
combined action in benign prostate cells has not yet been
evaluated. In this study, we observed that ROS generation
and mitochondrial function play a pivotal role in determina-
tion of PNT1A cell proliferation. On the one hand, DHA had
an anticlonogenic effect at the highest concentration tested
(100μM) after 48 h of incubation, mainly due to the increase
in ROS production, probably related to mitochondrial func-
tion impairment and AKT inactivation. On the other hand,
MLT, at the pharmacologic range, improved oxidative phos-
phorylation and decreased ROS production, but reduced cell
proliferation due to inhibition of survival pathways. More-
over, MLT improved the DHA antiproliferative effect in
PNT1A cells.
4.1. Benign Epithelial Prostatic Cells Respond Differently to
DHA than Tumor Cells. DHA has been described to have
antimitotic and proapoptotic effects on malignant prostate
cell lines using different concentrations [18, 34, 35]. How-
ever, in this study DHA had a hormetic behavior on nontu-
mor PNT1A cells, since an inhibitory effect on proliferation
was detected at a higher concentration (100μM) for longer
exposures (48 and 72 h), whereas a proliferative stimulus
was triggered at lower concentrations (20 and 50μM).
Despite not being the aim of our study, it is worth mention-
ing that the results from our laboratory (not shown) with
DHA 50μM for 48 h suggest that such an increase in cell pro-
liferation may be related to deregulation of peroxisome
proliferator-activated receptor gamma (PPARγ), which is still
under investigation. Regarding DHA at 100μM for 48 h, it is









































C DHA MLT DM
(c)
Figure 3: ROS determination. Production of (a) hydrogen peroxide (H2O2)—values show pmol of H2O2/min/10
6 cells and SEM; production
of (b) superoxide anion (O2
●−)—values show the fluorescence intensity (FI) per cell× 104. Legend of panels (a) and (b): C: control (vehicle
incubation); DHA: incubation with 100 μM of DHA for 48 h; MLT: incubation with 1μM of melatonin for 48 h; DM: coincubation with
100μM of DHA and 1μM of melatonin for 48 h. Statistical analysis: (A) different from C; (B) different from DHA; (C) different from
MLT. p < 0 05 was considered statistically different. Three independent experiments in triplicate were considered for statistical analysis of
H2O2 production and at least 250 cells for O2
●−. (c) Detection of O2
●− production after MitoSOX incubation. Images captured with 40x
objective with an inverted fluorescence microscope.
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increase in ROS production and the inactivation of AKT
(Figure 8(a)). Interestingly, previous studies demonstrated
that 50μM of DHA led to death of PC3 and DU145 cells
[18] whereas in our study this concentration stimulated
PNT1A to proliferate and cytotoxic effects were observed
solely at 100μM. In PCa, oxidative stress is increased and it
is possible that incubation with DHA enhanced cellular dam-
age, activating cell death even at lower concentrations. Fur-
thermore, this susceptibility may also rely on metabolic
changes among malignant transformations known as the
Warburg effect [36]. Regarding PCa, these changes may be
related to several mechanisms [37], as increased β-oxidation
[38], higher amounts of mitochondria and lower complex I
activity [4], mutations in ETC complexes [5], and alterations
in mitochondria dynamics [39] which may be related to dif-
ferent responses between benign and prostate tumor cells.
4.2. DHA Raised ROS Production and Mitochondrial
Rearrangement. To the best of our knowledge, this is the first
evidence that DHA increases ROS generation and decreases
cell proliferation in PNT1A benign prostate cells. Such effects
were probably associated to higher O2
●− production, which is
related to the increase in mitochondrial membrane potential
(Figure 5(d)) [40]. It is currently known that higher oxidative
stress levels commonly exhibit impairment of mitochondrial
activity [41]. In response to oxidative damage or metabolic
changes, mitochondrial fusion may be triggered as tentative
to restoration of organelle function [42]. In this context, we
hypothesize that DHA raised oxidative stress, therefore
impairing mitochondrial function, which then stimulated
organelle fusion and led to area and perimeter increase as well
as the recovery of oxidative phosphorylation (OXPHOS).
Mitochondrial morphology alterations described here are in
line with previous reports, since DHA upregulated the pro-
tein related to mitochondrial fusion MFN2 [43]. It is worth
mentioning that despite that OXPHOS was unchanged after
48 h of incubation, mitochondrial integrity probably
remained damaged because DHA strongly impaired MBRC,
an index of cell potential to respond upon stress conditions,
which is decreased under oxidative stress [44]. In this context,
in vitro studies from our research group found that half of










































































































Figure 4: Oxygen consumption rate of PNT1A cells after incubations. (a) Basal state (S2), (b) respiratory control ratio (OCR), (c) maximum
velocity of respiratory chain (S3U), and (d) mitochondrial bioenergetic reserve capacity (MBRC). Values show the mean of nmol of O2/10
6
cells/min and SEM. C: control (vehicle incubation); DHA: incubation with 100 μMof DHA for 48 h; MLT: incubation with 1μMof melatonin
for 48 h; DM: coincubation with 100 μM of DHA and 1 μM of melatonin for 48 h. Statistical analysis: (A) different from C; (B) different from
DHA; (C) different from MLT. p < 0 05 was considered statistically different. Three independent experiments were performed in triplicate
for statistical analysis.
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viability of the testis cell population in fetal mice and,
when combined to 2-monoethylhexyl phthalate (MEHP),
strongly impaired the survival of male germ cells
(gonocytes). Therefore, the data highlights the ability of
DHA to induce cell sensitization to other cytotoxic com-




























































Figure 5: Morphometric analysis of mitochondria. (a) Mitochondria labeling with MitoTracker, (b) area (μm2), (c) perimeter (μm), and
(d) mitochondrial membrane potential assessed with Safranin O. Images captured with 40x objective with an inverted fluorescence
microscope for morphological analysis. Legend: C: control (vehicle incubation); DHA: incubation with 100 μM of DHA for 48 h; MLT:
incubation with 1μM of melatonin for 48 h; DM: coincubation with 100 μM of DHA and 1μM of melatonin for 48 h; ADP: adenosine
diphosphate; OLG: oligomycin; AA: antimycin A. At least 100 cells from consecutive passages were considered for statistical analysis.
Values show the mean and SEM. Statistical analysis: (A) different from C; (B) different from DHA; (C) different from MLT. p < 0 05
was considered statistically different.
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Figure 6: Signaling pathways. (a) AKT, (b) mTOR, and (c) ERK1/2 activation. (d) GSTP1 and (e) AR expression. Legend of panels (a)–(e):
C: control (vehicle incubation); DHA: incubation with 100μM of DHA for 48 h; MLT: incubation with 1 μM of melatonin for 48 h; DM:
coincubation with 100μM of DHA and 1 μM of melatonin for 48 h. Values show the mean of relative density and SEM from three
different samples normalized to β-actin. For each blotting, the samples run in the same electrophoresis, and except for AR, the bands were
cropped, for group standard purposes. Statistical analysis of panels (a)–(e): (A) different from C; (B) different from DHA; (C) different
from MLT. (f) Cell proliferation rate after incubation with luzindole. Values show the mean of absorbance and SEM. Legend of panel (f):
LZ: luzindole. Statistical analysis of panel (f): ∗ different from incubation without luzindole. p < 0 05 was considered statistically different.
Three independent experiments were performed in triplicate (n = 9) for statistical analysis.
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4.3. Decrease in ROS Production by MLT Alone Is Associated
to Lower Cell Proliferation Rates. Because oxidative stress
apparently is a key factor for cell survival [18], we evaluated
the antioxidant potential of MLT. MLT is an expected anti-
oxidant agent which can scavenge free radicals directly or
by its metabolites [45], upregulate the expression and activity
of antioxidant enzymes, such as superoxide dismutase, gluta-
thione peroxidase, and catalase [46], or modulate mitochon-
drial activity [6, 47]. In the present study, our aim was to
validate on PNT1A cells the MLT antioxidant action and
not the mechanisms per se. Indeed, MLT was able to decrease
H2O2 and O2
●− production, combined or not to DHA. Our
data are in line with previous literature, since it was reported
that MLT, at the same concentration, decreased ROS in
isolated mitochondria from the liver [10]. Such an effect on
oxidative stress attenuation may be associated to the attenu-
ation of proton leak in mitochondria [48] or even decrease in
mitochondrial membrane potential, a well-known contribu-
tor to O2
●− production in vitro and in vivo [40]. Levels of
ROS production are closely related to OXPHOS [6], and
decrease in H2O2 and O2
●− described may be related to
improvement of the respiratory control ratio. It is worth
mentioning that complex II-supported respiration was cho-
sen based on the fact that such complex is invariable among
cancer cells [49] and it is an important site for ROS genera-
tion, while it also contributes to ROS either directly or indi-
rectly via reverse electron transfer [50]. To our knowledge,
this is the first report to show antioxidant properties of
MLT in PNT1A cells associated to improvement of the mito-
chondrial physiology. Because the increase in ROS genera-
tion had been related to expansion of mitochondrial area
and perimeter, we investigated if the decreased production
of reactive species associated to OXPHOS improvement also
affected organelle morphology. Thus, it was possible to
observe that mitochondrial function enhancement was
followed by decrease in organelle area and perimeter. The
findings herein suggest a quality control system that removes
fractions or the entirety of mitochondria with higher ROS
generation which may be harmful to organelle homeostasis.
On the other hand, we cannot discard that MLT effects on
mitochondria physiology may be a consequence of first
changes in organelle dynamics, as well as contribution of
antioxidant system enzyme modulation. Therefore, the pres-
ent study highlights new possibilities of MLT’s role as a reg-
ulator of mitochondrial function in prostatic epithelial cells.
The results observed here regarding proliferation of
PNT1A cells were different from the previous results [51],
since it was reported that MLT at 500μM or 10mM did
not affect cell proliferation. Such differences may be due to
conditions of incubation but also to higher cell density
seeded (104 cells/well) than what Gobbo and colleagues
[51] performed (3× 103 cells/well), which may be more suit-
able to clarify the differences between proliferation rates
among incubations. In the present study, OXPHOS improve-
ment and decrease in ROS production by MLT was probably
associated to AKT inactivation and decrease in cell prolifera-
tion. Our data may suggest an association with ATP, since its
increase may be associated to cell death [52]. MLT’s property
of modulating ATP levels was reported at different concen-
trations and systems due to several mechanisms, such as a
raise in ADP/O ratio and upregulation of β subunit of ATP
synthase [7–10]. Despite not being assessed, it is suggested
that OXPHOS improvement may be related to increase in
ATP levels in the cells. This hypothesis is in line with previ-
ous literature, since MLT in the liver and brain tissue, even
at lower concentrations (100 nM), was able to improve
OXPHOS through stimulation of complexes I and IV and
protection of these enzymes against oxidative damage, which
was closely related to increase in ATP production [7]. In this
context, the increase in ATP levels may suppress the AKT
pathway [53] and decrease survival, as observed here and
reported in breast cancer cells after administration of extra-
cellular ATP to the medium [54]. Therefore, this hormone
decreased cell proliferation probably due to the decrease in
ROS production that affected pathways of mitosis stimula-
tion and cell survivor. PCa progression is related to the rise
in oxidative stress and, together with our data, point to
mitochondrial bioenergetics’ role on cell arrest and suggest
that MLT is effective as antiproliferative agent acting in this
pathway (Figure 8(b)).
4.4. MLT Antioxidant Ability Apparently Is More Efficient at
the Mitochondrial Compartment. Higher lipid accumulation
probably was related to increased amounts of DHA. Such
omega-3 is metabolized primarily at the peroxisome fraction,
a well-known site of H2O2 generation, due to long-chain fatty
acid structure [19]. Regarding coincubation, H2O2 produc-
tion was increased and MLT was not able to decrease it.
Therefore, the antioxidant effects of MLT in the presence of
DHA were mainly at the mitochondrial compartment since,
despite not recovering to control levels, such hormone
decreased O2
●− levels possibly related to OXPHOS improve-






















Figure 7: Testosterone level in the medium. After incubations, the
medium was removed and testosterone level assessed by ELISA
assay. Values show mean of ng of testosterone/mL ×10−5
normalized by protein amount from cell lysate and SEM. Legend:
C: control (vehicle incubation); DHA: incubation with 100μM of
DHA for 48 h; MLT: incubation with 1μM of melatonin for 48 h;
DM: coincubation with 100μM of DHA and 1 μM of melatonin
for 48 h. Statistical analysis: (A) different from C. p < 0 05 was
considered statistically different. Three independent experiments
were performed in triplicate for statistical analysis.
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mitochondrial oxidative damage, which can be related to the
enhancement of MBRC observed in coincubation.
4.5. DHA and MLT Downregulate Cell Proliferation and
Survival Pathways. In PC3 and DU145 lines, DHA led to
AKT/mTOR suppression [18], whereas in PNT1A only the
activation of AKT decreased. This evidence may suggest a
different action of such omega-3 when distinct stages of pro-
liferative disorders are considered. Concerning MLT alone, it
suppressed the AKT/mTOR pathway, which is closely related
to decrease in cell proliferation. However, when coincubated
to DHA, MLT enhances the decrease in proliferation by acti-
vating ERK1/2. Despite being generally associated to prolifer-
ation stimulus, activation of ERK1/2 may also lead to cell
death mainly under stress conditions [55]. In PC3 cells, the
increase in oxidative stress reduced AKT activation, followed
by increased phosphorylation of ERK and cell proliferation
arrest [56], similar to what was observed in PNT1A in our
study after coincubation. Despite the fact that DHA alone
did not stimulate ERK1/2 activation, even under high ROS
production, in our in vitro model, this evidence highlights
that MLT could play a key role in the modulation of such
pathway. In addition, we also suggest that MLT combined
to increased oxidative stress, the ERK1/2 pathway is
strongly activated and therefore controls cell survival, as
reported previously [57]. It is worth mentioning that
higher levels of ERK activation may also be related to
GSTP1 upregulation [58].
Because androgen regulation is important for the survival
of prostate cells and PCa development, we analyzed if incu-
bation effects were related to the alteration in this pathway.
In the present incubations, DHA did not change testosterone
levels in medium or AR expression, which supports the
hypothesis that the antimitotic property of this omega-3 in
PNT1A cells was mainly due to alterations on oxidative sta-
tus. AR expression was also unchanged after MLT exposure,
regardless of DHA incubation. However, MLT influenced the
androgen levels in the medium, but due to methodologic lim-
itations, it is not clear if the release of testosterone or its
uptake was affected by MLT. Furthermore, Estrada and col-
leagues [59] demonstrated that in the presence of androgen,
ERK activation was increased and followed by cell prolifera-
tion decrease. Therefore, our study suggests that MLT may
improve antiproliferative effects due to an association
between mitochondrial bioenergetics, androgen pathway,
and ERK pathway, even in nontumor cells (Figure 8(c)),
although additional studies are needed to better understand
this issue.
Finally, we proved that PNT1A proliferation, when incu-
bated with MLT, was independent of MTR1 and MTR2 acti-
vation, both expressed in the prostate gland [60]. This




























































Figure 8: Proposed mechanism. (a) DHA increased ROS production, mainly O2
●−, leading to oxidative damage that may trigger
mitochondrial fusion as tentative to restoration of organelle function. Also, such fatty acid increased lipid accumulation which may
increase ROS. In this context, we hypothesize that DHA raised oxidative stress, therefore impairing mitochondrial function, which then
stimulated organelle fusion and led to area and perimeter increase as well as the recovery of OXPHOS, but not MBRC. In addition, DHA
also inhibited AKT activation which may be related to increase in oxidative damage and decrease in cell proliferation. (b) MLT decreased
ROS production, both O2
●− and H2O2, and improved OXPHOS which may be associated to AKT/mTOR inactivation. (c) DHA increased
oxidative damage which was not neutralized by MLT, but together (DM) amplified the antiproliferative effect probably due to AKT and
ERK1/2 regulation. MLT, alone or coincubated, stimulated ERK1/2 activation as well as androgen uptake, but the mechanism is not clear.
Also, MLT coincubated with DHA-stimulated GSTP1 expression probably due to ROS increase. Legend: DHA: docosahexaenoic acid;
MLT: melatonin; DM: coincubation; O2
●−: superoxide anion production; H2O2: hydrogen peroxide; ATP: adenosine triphosphate;
OXPHOS: oxidative phosphorylation; MBRC: mitochondrial bioenergetics reserve capacity; ROS: reactive oxygen species. Dashed lines,
mechanism proposed based on the literature; solid lines, effects and correlations based on observed results.
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reported previously [26], activated pathways regardless of
membrane receptors and had a key role in mitochondrial
activity modulation and oxidative stress control.
5. Conclusion
Our data indicates that PNT1A cells are less sensitive to DHA
than advanced cancer cell lines; however, at 100μM this
omega-3 reduced the proliferation rate due to the increase
in ROS production at cytotoxic levels and possibly associated
to the inhibition of AKT activation. It is important to empha-
size DHA hormetic behavior in PNT1A cells, because at
lower concentrations it stimulated cell proliferation. This
finding highlights the need for further studies, concerning
dietary supplementation with this PUFA, mainly in men at
risk of PCa development. Furthermore, MLT at 1μM
increased OXPHOS, decreased ROS production, and exerted
an antimitogenic effect via AKT inactivation and ERK1/2
activation regardless of binding in MTR1 or MTR2. More-
over, MLT improved in vitro DHA antiproliferative effect,
which may open new possibilities of chemopreventive strate-
gies, mainly at early stages of prostate proliferative disorders.
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